FDA Global Generic Drug Affairs (GGDA) is the dedicated team within the Office of Generic Drugs (OGD) that leads, coordinates, and manages OGD’s international activities, and it runs the Generic Drug Cluster, a confidential regulator-to-regulator forum. For overseas generic teams, GGDA is an information and engagement channel, not an approval service: it does not clear ANDAs, grant market access, or manage the separate FDA-EMA Parallel Scientific Advice (PSA) pilot for complex generics. This guide gives you a decision map to pick the right channel and a clear do / does-not-do table so you do not mistake engagement for approval.
What FDA Global Generic Drug Affairs Actually Is
GGDA sits inside FDA’s Office of Generic Drugs (OGD). OGD ensures, through a scientific and regulatory process, that Americans have access to safe, effective, and high-quality generic drugs, and one of the ways it does this is through international engagements. The role of the GGDA team is to lead, coordinate, and manage OGD’s international activities in collaboration with FDA Centers and Offices to advance the overall mission of OGD and FDA.
In practice, GGDA is the landing point for overseas generic teams who want to understand how FDA engages internationally on generic drug regulation. Its work covers harmonization of scientific and technical recommendations for generics under CDER international harmonization initiatives, regulatory strengthening and reliance, partnerships and information sharing, and setting international standards. GGDA also maintains the resource list that helps foreign counterparts navigate the U.S. generic drug program and the abbreviated new drug application (ANDA) submission process.
GGDA in one line
A coordination and engagement team inside OGD, not a review division and not an approval authority.
Decision Map: GGDA, the Generic Drug Cluster, or the PSA Pilot?
Overseas teams often confuse three related but distinct things. Use this decision map to identify which information channel applies to your situation before you act.
| If your need is… | The relevant channel is… | What it gives you | What it does NOT give you |
|---|---|---|---|
| Understanding FDA’s international generic engagement, harmonized guidances, and navigational resources for foreign counterparts and ANDA submitters | GGDA (the OGD team and its resource page) | Context on international activities, links to ANDA and product-specific guidance resources, and awareness of harmonization outcomes (e.g., M13A) | ANDA approval, submission clearance, or case-specific regulatory decisions |
| Understanding why leading regulators align on generic science and draft policy, and how confidential regulator-to-regulator exchange works | Generic Drug Cluster (led by FDA/GGDA) | Scientific alignment among regulatory agencies; outcomes that later appear in harmonized guidances and product-specific guidances | Direct industry participation, public release of topics discussed, or any approval action |
| Concurrent scientific advice from FDA and EMA while developing a complex generic or hybrid product, before submission | FDA-EMA PSA pilot (separate, applicant-facing program) | A joint meeting where FDA and EMA assessors exchange views on your specific development questions | Approval, ANDA clearance, or market authorization from either agency |
A quick rule of thumb: GGDA tells you how FDA engages globally; the Generic Drug Cluster is where regulators align with each other; the PSA pilot is where a complex-generics applicant talks to both FDA and EMA at once. If your question is about routine ANDA submission mechanics rather than complex-generics scientific advice, the PSA pilot is not your channel, and GGDA’s resource list will point you to the right submission path instead.
The Generic Drug Cluster: A Regulator-to-Regulator Forum
The Generic Drug Cluster is led by FDA and is a forum for the world’s leading regulatory agencies to address generic drug development globally. GGDA leads this Cluster as part of OGD’s international activities. It is important for overseas teams to understand that the Cluster is a regulator-to-regulator forum, not an industry-facing service and not an approval mechanism.
Cluster objectives
According to FDA, the Generic Drug Cluster aims to increase scientific alignment among leading generic regulatory agencies by fulfilling these objectives:
- Confidential policy exchange: offering a confidential forum for exchange of discussion on policies in development, including draft guidances for industry and the scientific basis for decisions on those policies. Participating agencies have Confidentiality Commitments, and the Cluster does not release information regarding the topics discussed. No guidance information is released outside the scope of the confidentiality commitment governing the Cluster.
- Common understanding of requirements: achieving a common understanding of each agency’s regulatory requirements for approval and current thinking on topics related to generic drug development through information sharing on approval requirements and recommendations conveyed in guidance documents.
- Scientific review alignment: providing a forum for discussion of general and product/class-related scientific review issues and fostering alignment in approaches to scientific evaluation whenever possible.
- Long-term safety: addressing long-term safety issues to ensure a global safety net for generic drugs through confidential sharing of reports.
How Cluster outcomes reach industry
Because the Cluster is confidential, overseas teams do not “join” it or receive its working papers. Its value reaches you indirectly, through harmonized outputs. A concrete example is the final guidance “M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms,” published by FDA alongside 814 revised product-specific guidances (PSGs) aligned with M13A. When you see aligned guidances or PSGs, that is often the visible downstream effect of regulator-to-regulator alignment work, not a benefit you apply for directly.
The FDA-EMA PSA Pilot: A Separate, Applicant-Facing Pathway for Complex Generics
The FDA-EMA Parallel Scientific Advice pilot is a distinct program that overseas teams should treat as an adjacent pathway, not as a GGDA approval service. FDA and the European Medicines Agency (EMA) launched the pilot to provide parallel scientific advice to applicants of ANDAs for FDA’s complex generic drug products and of marketing authorization applications (MAAs) for EMA’s hybrid products. It is an expansion of FDA and EMA’s existing parallel scientific advice for new drugs and biological products.
The PSA pilot is for prospective FDA ANDA applicants developing complex generics and EMA MAA applicants developing hybrid products; it provides concurrent scientific advice, not approval.
How the PSA pilot works
The pilot allows prospective applicants of ANDAs to FDA and MAAs to EMA to submit a request for a meeting with both agencies to discuss specific questions regarding the development of complex generic drug/hybrid products. The goal is to give FDA and EMA assessors a mechanism to concurrently exchange their views on scientific issues with applicants during the development phase of products that are generally more challenging to develop with traditional bioequivalence methods. Through the PSA process, applicants gain an understanding of both agencies’ recommendations.
Potential benefits include a deeper understanding of the basis for regulatory decisions from both agencies, optimized global product development programs, and avoidance of unnecessary replication of studies or unnecessary diverse testing methodologies. Industry can request PSA meetings by sending a single “Request for PSA” letter (justification letter) to both EMA and FDA (preANDAHelp@fda.hhs.gov). FDA and EMA published a “General Principles” document describing what to include in the request and the subsequent PSA processes.
Why this is separate from GGDA
The PSA pilot is administered jointly by FDA and EMA and is requested directly by applicants, whereas GGDA coordinates OGD’s broader international engagement and leads the regulator-to-regulator Generic Drug Cluster. Treating the PSA pilot as something GGDA “manages or grants” would misstate both programs. For routine pre-submission meeting mechanics and controlled correspondence under GDUFA, see the GDUFA III controlled correspondence decision map and the FDA generic drug meeting checklist, which cover the applicant-facing meeting channels most overseas teams actually use day to day.
What GGDA and the Cluster Do and Do Not Do
Use this do / does-not-do table to set correct expectations before you rely on any GGDA-related channel.
| Channel | Does | Does not do |
|---|---|---|
| GGDA | Leads, coordinates, and manages OGD international activities; leads the Generic Drug Cluster; collaborates on harmonization (e.g., M13A) and information sharing; provides a resource list for foreign counterparts and ANDA submitters | Grant ANDA approval; clear ANDA submissions; authorize U.S. market access; manage or grant the PSA pilot; provide case-specific regulatory decisions |
| Generic Drug Cluster | Provide a confidential regulator-to-regulator forum; exchange on draft policies and the scientific basis for decisions; foster scientific alignment; share long-term safety reports | Include industry applicants as participants; release topics discussed to the public; constitute any form of approval or submission clearance |
| FDA-EMA PSA pilot | Give concurrent scientific advice from FDA and EMA on complex generic/hybrid development questions; help optimize global development and reduce duplicated studies | Grant approval; clear an ANDA; authorize market access; apply to all generics or to innovator applicants; replace the standard ANDA review |
Common Misconception: Participation Is Not Approval
It is worth stating plainly because it is a frequent error: participation in GGDA initiatives or Generic Drug Cluster meetings does not constitute formal ANDA submission clearance or U.S. market authorization. The Cluster is a confidential forum among regulatory agencies, and GGDA is a coordination team. Neither one reviews, clears, or approves your ANDA. Only the standard OGD review of a complete ANDA can result in approval. Likewise, a PSA pilot meeting gives you concurrent scientific advice to inform your development plan; it does not pre-clear your application or bind either agency to approve it.
Practical Checklist for Overseas Teams
- Start by confirming which channel you actually need: engagement context (GGDA), regulator alignment awareness (Cluster), or complex-generics scientific advice (PSA pilot).
- If you are developing a complex generic and want joint FDA/EMA input, prepare a single “Request for PSA” justification letter and send it to both EMA and preANDAHelp@fda.hhs.gov, following the General Principles document.
- Do not expect the Generic Drug Cluster to share its working topics with you; look instead for its downstream outputs in harmonized guidances and PSGs.
- Never treat a GGDA engagement, a Cluster reference, or a PSA meeting as a substitute for, or guarantee of, ANDA approval.
Where to Go Next
- GDUFA III controlled correspondence decision map for routine written questions to FDA during generic development.
- FDA generic drug meeting checklist for preparing pre-ANDA and other generic drug meetings.
Sources
- FDA, “Global Generic Drug Affairs”: https://www.fda.gov/drugs/generic-drugs/global-generic-drug-affairs
- FDA, “FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products”: https://www.fda.gov/drugs/generic-drugs/fda-ema-parallel-scientific-advice-pilot-program-complex-generichybrid-products
This article is educational information, not legal/regulatory or medical advice. It is not medical advice, and it does not replace the regulations, FDA guidance documents, or advice from qualified regulatory counsel.